- Patients with NSCLC with epidermal growth factor receptor (EGFR) mutations and brain metastases >1 cm who underwent brain surgery in addition to EGFR-tyrosine kinase inhibitors (TKIs) and radiotherapy (RT) had better outcomes than those who received TKIs and RT alone.
Why this matters
- Studies suggest patients with NSCLC with an EGFR mutation have a greater risk for brain metastases.
- 100 patients with EGFR-positive NSCLC and brain metastases underwent brain surgery plus TKI therapy and RT (n=40) or TKI and RT alone (n=60).
- Median follow-up, 25.6 months.
- Funding: Kaohsiung Medical University Hospital; others.
- Mean survival was significantly better in the brain surgery group (21.9 vs 15.6 months; P=.026).
- After multivariable analysis, brain surgery was not associated with better OS in the overall cohort (HR, 0.69; P=.134).
- However, brain surgery significantly improved OS in patients with brain metastases >1 cm (aHR, 0.49; P=.008).
- Retrospective, single-center study.